Viridian Therapeutics Prepares for Transformational 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Nasdaq notches record high close as investors focus on earnings
TD Cowen on Viridian Therapeutic (VRDN): 'VRDN is a Top Pick'
January 6, 2026 3:14 PM ESTTD Cowen analyst Joseph Thome reiterated a Buy rating on Viridian Therapeutic (NASDAQ: VRDN).
The analyst comments "VRDN provided a roadmap for a busy 2026. A BLA for veligrotug in TED is under priority review with a June 30, 2026 PDUFA date set.... More



